Ascend Capital’s DexCom DXCM Stock Holding History

Ascend Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-264,000	Closed	-$5.41M	–	114
2015 Q4	$5.41M	Buy	+264,000	New	+$5.49M	0.19%	105

Other funds holding DXCM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Ascend Capital's DXCM Position: Q1 2016 in Review

Ascend Capital sold out of DexCom (DXCM) in Q1 2016, closing a stake of 264,000 shares — an estimated $5.41M sold.

Ascend Capital first reported a position in DXCM in Q4 2015 and held it in 1 quarter. The position peaked at $5.41M in Q4 2015. 264 funds tracked by Wall St. Rank hold DXCM as of Q1 2016.

Ascend Capital reported no remaining DexCom position as of Q1 2016 after selling out during the quarter.
Ascend Capital sold 264,000 DexCom shares in Q1 2016, an estimated $5.41M.
Ascend Capital first reported a position in DexCom in Q4 2015 and held it in 1 quarter.
Ascend Capital's DexCom position peaked at $5.41M in Q4 2015.
264 funds tracked by Wall St. Rank held DexCom as of Q1 2016.

Based on Ascend Capital's 13F filing for Q1 2016, filed 13 May 2016.